Abbott Laboratories (NYSE:ABT) Stock Has Average Target Price of $118.32 According to Brokerages

Key Points

• Analysts maintain a favorable view of Abbott: Twenty-eight firms give the stock a consensus “Moderate Buy” rating, with an average 12-month price target of $118.32 versus its recent price of $103.70.
• Abbott’s third-quarter results met expectations, with EPS of $1.42 and revenue of $13.01 billion, up 14.5% year over year. The company also declared a quarterly dividend of $0.63 per share, representing a 2.4% annualized yield.
• Key risks remain: Investors are concerned about reduced 2026 sales-growth guidance, diabetes-related pricing pressure, weakness in electrophysiology, and uncertainty surrounding the planned 2027 spin-off of the $8.5 billion Nutrition business.

Abbott Laboratories (NYSE:ABT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-eight ratings firms that are presently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation, twenty-two have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $118.32.

Several equities analysts have recently issued reports on ABT shares. Wall Street Zen upgraded Abbott Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday. Citigroup cut their price objective on Abbott Laboratories from $125.00 to $122.00 and set a "buy" rating for the company in a report on Thursday. JPMorgan Chase & Co. decreased their target price on Abbott Laboratories from $120.00 to $118.00 and set an "overweight" rating for the company in a research note on Thursday. Royal Bank Of Canada cut their price target on shares of Abbott Laboratories from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Thursday. Finally, UBS Group reduced their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday, July 28th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. IVC Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $241,000. Holos Integrated Wealth LLC boosted its stake in shares of Abbott Laboratories by 40.3% during the 3rd quarter. Holos Integrated Wealth LLC now owns 888 shares of the healthcare product maker's stock worth $92,000 after acquiring an additional 255 shares in the last quarter. Kingswood Wealth Advisors LLC boosted its stake in shares of Abbott Laboratories by 7.3% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 12,712 shares of the healthcare product maker's stock worth $1,257,000 after acquiring an additional 863 shares in the last quarter. Financial Management Professionals Inc. grew its holdings in shares of Abbott Laboratories by 2.1% in the 3rd quarter. Financial Management Professionals Inc. now owns 5,878 shares of the healthcare product maker's stock worth $581,000 after acquiring an additional 119 shares during the last quarter. Finally, Compass Ion Advisors LLC grew its holdings in shares of Abbott Laboratories by 7.0% in the 3rd quarter. Compass Ion Advisors LLC now owns 5,106 shares of the healthcare product maker's stock worth $505,000 after acquiring an additional 332 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Trading Up 0.0%

Shares of NYSE:ABT opened at $103.70 on Monday. The company has a 50 day moving average of $105.15 and a 200-day moving average of $98.29. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The firm has a market cap of $179.45 billion, a P/E ratio of 38.70, a P/E/G ratio of 1.82 and a beta of 0.59. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $132.02.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts' consensus estimates of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The business had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. During the same quarter last year, the business earned $1.30 earnings per share. The business's revenue for the quarter was up 14.5% on a year-over-year basis. As a group, analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 94.03%.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.